What is hidden behind peptide bond restriction and α-carbon asymmetry of conserved antigens? Peptide bond isosters and chirally transformed pseudopeptides as novel elements for synthetic vaccines and therapeutic agents against malaria

Current Organic Chemistry

Volumn 10, Issue 4, 2006, Pages 433-456

  Lozano, José Manuel ^a,b   Salazar, Luz Mary ^a,b   Rivera, Zuly ^a   Patarroyo, Manuel Elkin ^a,b  

^a FUNDACIÓN INSTITUTO DE INMUNOLOGÍA DE COLOMBIA FIDIC   (Colombia)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

Homochirality; Molecular orbital system; Peptide bond surrogates; Peptide based vaccine; Plasmodium falciparum

Indexed keywords

AMINO ACIDS; ANTIGENS; BINDING ENERGY; CARBON; DISEASES; IMMUNE SYSTEM; MOLECULAR ORBITALS; PEPTIDES; STEREOCHEMISTRY; VACCINES;

AMINO ACIDS COMPOSITIONS; HOMOCHIRALITY; IMMUNOGENS; L-AMINO ACIDS; MOLECULAR ORBITAL SYSTEM; PEPTIDE BOND SURROGATE; PEPTIDE BONDS; PEPTIDE-BASED VACCINE; PLASMODIUM FALCIPARUM; PSEUDO-PEPTIDE;

LIGANDS;

ALANINE; ANTIMALARIAL AGENT; ASPARTIC ACID; DEXTRO ALANINE; LYSINE; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; PROTEINASE INHIBITOR; PSEUDOPEPTIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VALINE;

AMINO ACID COMPOSITION; ANTIMALARIAL ACTIVITY; CHEMICAL MODIFICATION; CHIRALITY; CIRCULAR DICHROISM; DRUG DESIGN; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ERYTHROCYTE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSTIMULATION; MALARIA; NONHUMAN; PARASITE IMMUNITY; PEPTIDE SYNTHESIS; PHYSICAL CHEMISTRY; PLASMODIUM FALCIPARUM; RECEPTOR BINDING; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 33645986520     PISSN: 13852728     EISSN: None     Source Type: Journal    
DOI: 10.2174/138527206776055358     Document Type: Review

References (83)

1. MacDermontt, A. Cosmic asymmetry: the meaning of life, Chemistry in Britain, 1994, 30, 487.
2. Bonner, W.A. The origin and amplification of biomolecular chirality. Orig. Life Evol. Biosph., 1991, 21(2), 59-111.
3. Hazen, R.M., Filley, T.R., Goodfriend, G.A. Selective adsorption of L- and D-amino acids on calcite: Implications for biochemical homochirality. Proc. Natl. Acad. Sci. USA. 2001, 98(10), 5487-90.
4. Croning, J.R. and Pizzarello, S. Enantiomeric excess in meteoritic amino acids. Science 1997, 275, 951-955.
5. Kondepudi, D.K. and Nelson, G.W. Weak neutral currents and the origin of biomolecular chirality. Nature 1985, 314, 438-441.
6. Siegel, J.S. Homochiral imperative of molecular evolution. Chirality 1998, 10, 24-27.
7. Saghatelian, A., Yokobayashi, Y., Soltani, K., Ghadiri, M. R. A chiroselective peptide replicators. Nature 2001, 409, 797-801.
8. Soai, K., Shibata, T., Morioka, H. and Choji, K. Asymmetric autocatalysis and amplification of enantiomeric excess of a chiral molecule. Nature 1995, 378, 767-768.
9. Lee, D.H., Granja, J.R., Martinez, J., Severin, K. and Ghadiri M.R. A self-replicating peptide. Nature 1996, 382, 525-528.
10. Bolli, M., Micura, R. and Eschenmoser, A. Pyranosyl-RNA: chiroselective self-assembly of base sequences by ligative oligomerization of tetranucleotide-2′,3′-cyclophosphates. Chem. Biol. 1997, 4, 309-320.
11. Kondepudi, D.K., Kaufman, R.J. and Singh, N. Chiral symmetry breaking in sodium chlorate crystallization. Science 1990, 250, 975-977.
12. Smyth, J.R. and Bish, D.L. Crystal structures and cation sites of the rock-forming minerals. Allen and Unwin, Boston, 1998.
13. Ertem, G., Ferris, J.P. Template-directed synthesis using the heterogeneous templates produced by montmorillonite catalysis. A possible bridge between the prebiotic and RNA worlds. J. Am. Chem. Soc. 1997, 119, 7197-7201.
14. Ramachandran, G.N., Ramakrisnan, C. and Sasisekharan, V. Stereochemistry of polypeptide chain configurations. J. Mol. Biol. 1963, 7, 95-99.
15. Hill, R.R., Birch, D., Jeffs, G.E., North, M. Enantioselection in peptide bond formation. Org. Biomol. Chem. 2003, 1(6), 965-72.
16. Marraud, G., Dupont, V., Grand, V. et al. (1993) Modifications in the amide bond and conformational constraints in pseudopeptide analogues. Biopolymers 33, 1135-1148.
17. Li, K., Foy, E., Ferreon, J.C., Nakamura, M., Ferreon, A.C., Ikeda, M., Ray, S.C., Gale, M. Jr., Lemon, S.M. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. USA. 2005, 102(8), 2992-2997.
18. Kontogiorgis, C.A., Papaioannou, P., Hadjipavlou-Litina, D.J. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results. Curr. Med. Chem. 2005, 12(3), 339-355.
19. Fletcher, A.P., Alkjaersig, N. and Sherry, S. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. I. the significance of fibrinogen proteolysis and circulating fibrinogen breakdown products. J. Clin. Invest. 1962, 41(4), 896-916.
20. Spatola, A. Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, Weinstein B., De., Marcel Dekker, eds, New York, 1993, Vol. 7, pp. 267-357.
21. Heitsch, H. Non-peptide antagonists and agonists of the bradykinin B(2) receptor. Curr. Med. Chem. 2002, 9, 913-928
22. Reichelt, A., Gaul, C., Frey, R.R., Kennedy, A., Martin, S.F. Design, synthesis, and evaluation of matrix metalloprotease inhibitors bearing cyclopropane-derived peptidomimetics as P1′ and P2′ replacements. J. Org. Chem. 2002, 67(12) 4062-4075.
23. Gambari, R. Peptide-nucleic acids (PNAs): a tool for the development of gene expression modifiers. Curr. Pharm. Des. 2001, 17, 1839-1362.
24. Cirillo, R., Astolfi, M., Conte, B., Lopez, G., Parlani, M., Sacco, G., Terracciano, R., Fincham, C.I., Sisto, A., Evangelista, S., Maggi, C.A., Manzini, S. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist. Neuropeptides 2001, 35(3-4), 137-147.
25. Xu, Y., Yamamoto, N. and Janda, K. Catalytic antibodies: hapten design strategies and screening methods. Bioorg. Med. Chem. 2004, 12(20), 5247-5268.
26. Chorev, M. and Goodman, M. Recent developments in retro peptides and proteins - an ongoing topochemical exploration. Trends Biotechnol. 1995, 13(10), 438-45.
27. Stern, P.S., Chorev, M., Goodman, M., Hagler, A.T. Computer simulation of the conformational properties of retro-inverso peptides. II. Ab initio study, spatial electron distribution, and population analysis of N-formylglycine methylamide, N-formyl N'-acetyldiaminomethane, and N-methylmalonamide. Biopolymers. 1983, 22(8), 1901-1907.
28. Ribeiro, A., Chorev, M., Goodman, M. Proton NMR studies of partially modified retro- inverso peptides. Biopolymers. 1983, 22(8), 1869-1883.
29. Guichard, G., In: Kates, S. and Albericio, F., eds. Solid-Phase Synthesis. Marcel Dekker eds, New York, 2000, pp 649-703.
30. Meguid, A., Metcalf, B. & Meek, T. An orally bioactive HIV-1 protease inhibitor containing an imidazole-derived peptide bond replacement: crystallographic and pharmacokinetic analysis. Biochemistry 1994, 33(39), 11671-11677.
31. N]Pro linkages in HIV protease inhibitors. J. Org. Chem. 1991, 56, 4161-4167.
32. Fraser, M., Strynadka, N., Bartlett, P., Hanson, J. and James, M. Crystallographic analysis of transition-state mimics bound to penecillopepsin: phosporous-containing peptide analogues. Biochem. 1992, 31, 5201-5214.
33. Mulichak, A., Hui, J., Tomasselli, A. The crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors. J. Biol. Chem. 1993, 268(18), 13103-13109.
34. Toh, H., Kikuno, R., Hayashida, H., Miyata, T., Kugimiya, W., Inouye, S., Yuki, S., Saigo, K. Close structural resemblance between putative polymerase of a Drosophila transposable genetic element 17.6 and pol gene product of Moloney murine leukaemia virus. EMBO J. 1985, 4(5), 1267-1272.
35. Ceccherini-Silberstein, F., Erba, F., Gago, F., Bertoli, A., Forbici, F., Bellocchi, M.C., Gori, C., D'Arrigo, R., Marcon, L., Balotta, C., Antinori, A., Monforte, A.D., Perno, C.F. Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. AIDS. 2004, 18(12), F11-9.
36. Brynda, J., Rezacova, P., Fabry, M., Horejsi, M., Stouracova, R., Sedlacek, J., Soucek, M., Hradilek, M., Lepsik, M., Konvalinka, J.A. phenylnorstatine inhibitor binding to HIV-1 protease: geometry, protonation, and subsite-pocket interactions analyzed at atomic resolution. J. Med. Chem. 2004, 47(8), 2030-2036.
37. Chen, S.W., Chiu, H.C., Liao, W.H., Wang, F.D., Chen, S.S., Wang, C.T. The virus-associated human immunodeficiency virus type 1 Gag-Pol carrying an active protease domain in the matrix region is severely defective both in autoprocessing and in trans processing of gag particles. Virology 2004, 318(2), 534-541.
38. Poorman, R.A., Tomasselli, A. G., Heinrikson, R. L., Kezdy, F.J. A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base J. Biol. Chem. 1991, 266, 14554-14561.
39. Grinde, B., Cameron, C. E., Leis, J., Weber IT, Wlodawer A, Burstein H, Skalka AM. Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates. J. Biol. Chem. 1992, 267, 9491-9498.
40. Cameron, C.E., Grinde, B., Jentoft, J., Leis, J., Weber, I.T., Copeland, T.D., Wlodawer, A. Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins. J. Biol. Chem. 1992, 267(33), 23735-23741.
41. Tossi, A., Benedetti, F., Norbedo, S., Skrbec, D., Berti, F., Romeo, D. Small hydroxyethylene-based peptidomimetics inhibiting both HIV-1 and C. albicans aspartic proteases. Bioorg. Med. Chem. 2003, 11(22), 4719-4727.
42. Sheha, M.M., el-Koussi, N.A., Farag, H.H. Brain delivery of HIV protease inhibitors. Arch Pharm (Weinheim). 2003, 336(1), 47-52.
43. Dauber, D.S., Ziermann, R., Parkin, N., Maly, D.J., Mahrus, S., Harris, J.L., Ellman, J.A., Petropoulos, C., Craik, C.S. Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease. J. Virol. 2002, 76(3), 1359-1368.
44. 2NH peptide bond isostere. Pergamon Journals Ltd. 1987, 119-121.
45. 2NH] pseudopeptide analogues of a highly potent somatostatin octapeptide. J. Med. Chem. 1987, 30, 1162-1166.
46. Fletcher, M.D. and Campbell, M. (1998). Partially modified retro-inverso peptides: development, synthesis and conformational behavior. Chemical Reviews 1990, 98(2), 763-795.
47. Fehrentz, J.A. and Castro, B. An efficient synthesis of optically active α-(t-butoxycarbonylamino)-aldehides from α-amino acids. Synthesis 1983, 676-678.
48. Merrifield, R.B. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 1963, 85, 2149.
49. Houghten, R.A. General method for the rapid solid-phase peptide synthesis of the large number of peptides: specificity of antigen-antibody interactions of the level of individual amino acids. Proc. Natl. Acad. Sci. USA 1985, 82, 5131.
50. Owusu-Apenten, R. Colorimetric analysis of protein sulfhydyl groups in milk: applications and processing effects. Crit. Rev. Food Sci. Nutr. 2005, 45(1), 1-23.
51. Chorev, M. The Partial Retro-Inverso Modification: A Road Traveled Together. Biopolymers 2005, 80, 67-84.
52. Bastian, M., Lozano, J.M., Patarroyo, M. E., Pluschke, G. and Daubenberger, C.A. Characterization of a reduced peptide bond analogue of a promiscuos CD4 T cell epitope derived from the Plasmodium falciparum malaria vaccine candidate merozoite surface protein 1. Molecular Immunology. 2004, 41, 775-784.
53. Violette, A., Averlant-Petit, M.C., Semetey, V., Hemmerlin, C., Casimir, R., Graff, R., Marraud, M., Briand, J.P., Rognan, D., Guichard, G. N,N'-Linked Oligoureas as Foldamers: Chain Length Requirements for Helix Formation in Protic Solvent Investigated by Circular Dichroism, NMR Spectroscopy, and Molecular Dynamics. J. Am. Chem. Soc. 2005, 127(7), 2156-2164.
54. Tropical Disease Research: progress Thirteenth Programme Report of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, Geneva, 1997, pp 40-61.
55. Kauth, C., Epp, C., Bujard, H. and Lutz, R. The Merozoite Surface Protein 1 complex of human malaria parasite Plasmodium falciparum. J. Biol. Chem. 2003, 278: 22257-22264.
56. Tanabe, K., Makay, M., Goman, M., Scaife, J.G. Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum. J. Mol. Biol. 1987, 195, 273-287.
57. Patarroyo, M.E., Romero, P., Torres, M.L., Clavijo P, Moreno A, Martinez A, Rodriguez R, Guzman F, Cabezas E. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 1987, 328, 629-632.
58. Jiang, G., Daubenberger, C., Huber, W., Matile, H., Tanner, M. and Pluschke, G. Sequence diversity of the merozoite surface protein 1 of Plasmodium falciparum in clinical isolates from the Kilombero District, Tanzania. Acta Trop. 2000, 74, 51-61.
59. Miller, L. H., Good M. F. and Kaslow, D. C. Vaccines against the blood stages of falciparum malaria. Adv. Exp. Med. Biol. 1998, 452, 193-205.
60. Gilbert, S.C., Plebansky, M., Gupta, S., Morris, J., Cox, M., Aidoo M, Kwiatkowski D, Greenwood BM, Whittle HC, Hill AV. Association of malaria parasite population structure, HLA, and immunological antagonism. Science 1998, 279, 1173-1177.
61. Plebanski, M., Aidoo, M., Whittle, H.C., Hill, A.V. Precursor frequency analysis of cytotoxic T lymphocytes to pre-erythrocytic antigens of Plasmodium falciparum in West Africa. J. Immunol. 1997, 158(6), 2849-2855.
62. 33 as a non-covalently associated complex with other fragments of the MSP-1. Mol. Biochem. Parasitol. 1992, 50, 307-316.
63. Holder, A., Lockyer, M.J., Odink, K.G. Primary structure of the precursor to the three major antigens of Plasmodium falciparum merozoites, Nature 1985, 317270-31273.
64. Egan, A. F., Burghaus, P., Druilhe, P., Holder, A.A., Riley, E.M. Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro, Parasite Immunol. 1999, 21133-21139.
65. Urquiza, M., Rodriguez, L.E., Suarez, J.E., Guzman, F., Ocampo, M., Curtidor, H., Segura, C., Trujillo, E., Patarroyo, M.E. Identification Plasmodium falciparum MSP-1 peptides able to bind to human red blood cells. Parasite Immunology 1996, 18, 505-526.
66. Carvalho, L.J., Oliveira, S.G., Theisen, M., Alves, F.A., Andrade, M.C., Zanini, G.M., Brigido, M.C., Oeuvray, C., Povoa, M.M., Muniz, J.A., Druilhe, P., Daniel-Ribeiro, C.T. Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels. Scand J. Immunol. 2004, 59(4), 363-372.
67. Rodriguez, R., Moreno, A., Guzmán, F., Calvo, M. and Patarroyo, M.E. Studies in owl monkeys leading to the development of a synthetic vaccine against the asexual blood stages of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 1990, 43, 339-354.
68. Patarroyo, M.E., Amador, R., Clavijo, P., Moreno, A., Guzmán, F., Romero, P., Tascón, R., Franco, A., Murillo, L.A., Pontón, G. and Trujillo, G. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria vaccine. Nature 1988, 332, 158-161.
69. Van Regenmortel, M.H. Antigenicity and immunogenicity of synthetic peptides. Biologicals. 2001, 29(3-4), 209-213.
70. Lioy, E., Suarez, J., Guzmán, F., Siegrist, S., Pluschke, G. and Patarroyo, M. E. Synthesis, Biological, and Immunological Properties of Cyclic Peptides from Plasmodium Falciparum Merozoite Surface Protein-1. Angewandte Chemie Int. Ed. 2001, 40, 2631-2635.
71. Valero, M.L., Camarero, J.A., Haack, T., Mateu, M.G., Domingo, E., Giralt, E., Andreu, D. Native-like cyclic peptide models of a viral antigenic site: finding a balance between rigidity and flexibility. J. Mol. Recognit. 2000, 13(1), 5-13.
72. Moreno, R., Jiang, L., Moehle, K., Zurbriggen, R., Gluck, R., Robinson, J.A., Pluschke, G. Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design. Chembiochem. 2001, 2(11), 838-843.
73. Bianco, A., Zabel, C., Walden, P., Jung, G. N-Hydroxy-amide analogues of MHC-class I peptide ligands with nanomolar binding affinities. J. Pept. Sci. 1998, 4(8), 471-478.
74. Calbo, S., Guichard, G., Muller, S., Kourilsky, P., Briand, J.P., Abastado, J.P. Antitumor vaccination using a major histocompatibility complex (MHC) class I-restricted pseudopeptide with reduced peptide bond. J. Immunother. 2000, 23(1), 125-130.
75. Lozano, J.M., Espejo, F., Diaz, D., Salazar, L.M., Rodriguez, J., Pinzón, C., Calvo, J.C., Guzmán, F., Patarroyo, M.E. Reduced amide pseudopeptide analogs of a malaria peptide possess secondary structural elements responsible for induction of functional antibodies which react with native proteins expressed in Plasmodium falciparum erythrocyte stages, J. Peptide Res. 1998, 52(6) 457-469.
76. Stemmer, C., Quesnel, A., Prevost-Blondel, A., Zimmermann, C., Muller, S., Briand, J.P., Pircher, H. Protection against lymphocytic choriomeningitis virus infection induced by a reduced peptide bond analogue of the H-2Db-restricted CD8(+) T cell epitope GP33. J. Biol. Chem. 1999, 274(9), 5550-5556.
77. Espejo, F., Bermudez, A., Torres, E., Urquiza, M., Rodriguez, R., Lopez, Y., Patarroyo, M.E. Shortening and modifying the 1513 MSP-1 peptide's alpha-helical region induces protection against malaria. Biochem. Biophys. Res. Commun. 2004, 315(2), 418-427.
78. Lozano, J.M., Espejo, F., Ocampo, M., Salazar, L.M., Tovar, D., Barrera, N., Guzmán, F. and Patarroyo M.E. Mapping the anatomy of a Plasmodium falciparum MSP-1 epitope using pseudopeptide-induced mono- and poly-clonal antibodies and CD and NMR conformation analysis. J. Struct. Biol. 2004, 148, 110-122.
79. Pfeiffer, B., Peduzzi, E., Moehle, K., Zurbriggen, R., Gluck, R., Pluschke, G., Robinson, J.A. A virosome-mimotope approach to synthetic vaccine design and optimgation: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate. Angew. Chem. Int. Ed. Engl. 2003, 42(21), 2368-2371.
80. Darko, C.A., Angov, E., Collins, W.E., Bergmann-Leitner, E.S., Girouard, A.S., Hitt, S.L., McBride, J.S., Diggs, C.L., Holder, A.A., Long, C.A., Barnwell, J.W., Lyon, J.A. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous crythrocytic-stage parasites. Infect Immun. 2005, 73(1), 287-297.
81. Espejo, F., Cubillos, M., Salazar, L.M., Guzmán, F., Urquiza, M., Ocampo, M., Silva, Y., Rodríguez, R., Lioy, E., Patarroyo, M.E. Structure, immunogenicity, and protectivity relationship for the 1585 malarial peptide and its substitution analogs, Angew. Chem. Int. Ed. 2001, 40, 4654-4657.
82. 42 pseudopeptides. Biochem. Biophys. Res. Comm. 2005, 329, 1053-1066.
83. Lozano, J.M., Tovar, D.R., Salazar, L.M., Ocampo, M., Guzmán F. and Patarroyo, M.E. Effects of a Specific Peptide Bond Replacement on a Plasmodium falciparum Protein Primary Processing In: Peptide Revolution: Genomics, Proteomics & Therapeutics, Michael Chorev and Tomi K. Sawyer (Eds). American Peptide Society, San Diego, 2003, pp. 991-993.